Literature DB >> 23527828

Do medicinal chemists learn from activity cliffs? A systematic evaluation of cliff progression in evolving compound data sets.

Dilyana Dimova1, Kathrin Heikamp, Dagmar Stumpfe, Jürgen Bajorath.   

Abstract

Activity cliffs are defined as pairs of structurally similar compounds with a significant difference in potency. These compound pairs have high SAR information content because they represent small structural changes leading to large potency alterations. Accordingly, activity cliffs are of prime interest for SAR exploration and compound optimization. It is currently unknown to what extent activity cliff information is utilized in practical medicinal chemistry. Therefore, we have assembled 56 compound data sets that evolved over time and searched for analogues of activity cliff-forming compounds with further increased potency. For ∼75% of all activity cliffs, there was no evidence for further chemical exploration. For ∼25% of all cliffs, potency progression was detected. In total, for ∼15% of all activity cliffs, positive cliff progression was observed that often involved multiple analogues. Given these findings, chemically unexplored activity cliffs should provide significant opportunities for further study in medicinal chemistry.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23527828     DOI: 10.1021/jm400147j

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

Review 1.  Automating drug discovery.

Authors:  Gisbert Schneider
Journal:  Nat Rev Drug Discov       Date:  2017-12-15       Impact factor: 84.694

2.  Discovery and synthetic optimization of a novel scaffold for hydrophobic tunnel-targeted autotaxin inhibition.

Authors:  Lauren E Ragle; Dilip J Palanisamy; Margaux J Joe; Rachel S Stein; Derek D Norman; Gabor Tigyi; Daniel L Baker; Abby L Parrill
Journal:  Bioorg Med Chem       Date:  2016-08-04       Impact factor: 3.641

3.  Advancing the activity cliff concept.

Authors:  Ye Hu; Dagmar Stumpfe; Jürgen Bajorath
Journal:  F1000Res       Date:  2013-09-30

4.  Cheminformatics analysis of the AR agonist and antagonist datasets in PubChem.

Authors:  Ming Hao; Stephen H Bryant; Yanli Wang
Journal:  J Cheminform       Date:  2016-07-08       Impact factor: 5.514

5.  Implications of Additivity and Nonadditivity for Machine Learning and Deep Learning Models in Drug Design.

Authors:  Karolina Kwapien; Eva Nittinger; Jiazhen He; Christian Margreitter; Alexey Voronov; Christian Tyrchan
Journal:  ACS Omega       Date:  2022-07-19

6.  Nonadditivity in public and inhouse data: implications for drug design.

Authors:  D Gogishvili; E Nittinger; C Margreitter; C Tyrchan
Journal:  J Cheminform       Date:  2021-07-02       Impact factor: 5.514

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.